In last trading session, Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) saw 0.14 million shares changing hands with its beta currently measuring 0.36. Company’s recent per share price level of $0.34 trading at -$0.01 or -3.65% at ring of the bell on the day assigns it a market valuation of $27.07M. That closing price of BCLI’s stock is at a discount of -526.47% from its 52-week high price of $2.13 and is indicating a premium of 61.76% from its 52-week low price of $0.13. Taking a look at company’s average trading volume volume of 781.83K if we extend that period to 3-months.
For Brainstorm Cell Therapeutics, Inc. (BCLI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) trade information
Upright in the red during last session for losing -3.65%, in the last five days BCLI remained trading in the red while hitting it’s week-highest on Thursday, 06/27/24 when the stock touched $0.34 price level, adding 11.89% to its value on the day. Brainstorm Cell Therapeutics, Inc.’s shares saw a change of 24.58% in year-to-date performance and have moved -13.06% in past 5-day. Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) showed a performance of -31.98% in past 30-days.
Brainstorm Cell Therapeutics, Inc. (BCLI) estimates and forecasts
Statistics highlight that Brainstorm Cell Therapeutics, Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added 19.33% of value to its shares in past 6 months, showing an annual growth rate of 45.10% while that of industry is 15.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.57% during past 5 years.
BCLI Dividends
Brainstorm Cell Therapeutics, Inc. is more likely to be releasing its next quarterly report in August and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
